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ABSTRACT
This report describes an outbreak of Legionnaires’
disease in severely immunosuppressed patients
hospitalised at a cancer centre. Universal urine
antigen testing and early levoﬂoxacin therapy
appeared to lower case fatality rates in compar-
ison with previous reports concerning this high-
risk population. This diagnostic and therapeutic
strategy should be considered when facing a
nosocomial outbreak of Legionnaires’ disease in
immunosuppressed hosts.
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A reduction in case fatality rates among non-
immunosuppressed patients with Legionnaires’
disease (LD) has recently been observed, suggest-
ing that new management strategies may result in
improved outcome [1–6]. These new approaches
include the use of urinary antigen testing for
rapid diagnosis in combination with highly active
antimicrobial agents against Legionella, e.g., azi-
thromycin and ﬂuoroquinolones [7,8]. However,
little is known about the potential impact of these
new strategies on immunosuppressed patients,
who have the highest mortality rates. Accord-
ingly, this report describes the impact of these
new diagnosis and treatment strategies on an
outbreak of LD caused by Legionella pneumophila
serogroup 1 among severely immunosuppressed
patients hospitalised at a cancer centre.
The outbreak of LD occurred over a 4-week
period among patients in a 300-bed tertiary
referral cancer centre for adults in Barcelona,
Spain. The hospital opened in 1991 and no
previous cases of nosocomial LD had been
observed. The ﬁrst case of Legionella pneumonia
was detected on 24 February 2005. When two
further cases were diagnosed within 48 h, Legio-
nella urinary antigen testing was instituted for all
patients hospitalised in the same wards as the ﬁrst
three cases, and for any patient presenting with a
new onset of fever or respiratory symptoms
(n = 155 patients). L. pneumophila serogroup 1
antigen in urine was detected using the NOW
Legionella Urinary Antigen test (Binax, Scarbor-
ough,MA,USA). The test was performed on a 24-h
basis, 7 days a week. To exclude false-positive
results, all urine samples were boiled and concen-
trated. All patients with a positive urine antigen
test underwent a chest radiograph and were
given early intravenous levoﬂoxacin therapy,
whether or not they presented with pneumonia.
Samples for microbiological investigations
were obtained from patients with pneumonia
whenever possible, and also from the water
system supply. All samples were cultured on
selective buffered charcoal yeast extract-a med-
ium, and pulsed-ﬁeld gel electrophoresis typing
was performed for all isolates [9].
The attributable case fatality rate was deﬁned
as death during symptomatic infection or as a
consequence of its complications. The overall case
fatality rate was deﬁned as death from any cause
within 28 days of the diagnosis. Table 1 shows
the characteristics of the 12 patients involved in
the outbreak. Three patients had profound neu-
tropenia (<0.1 · 109 cells ⁄L), and one also had
invasive pulmonary aspergillosis; this patient’s
condition was complicated by diffuse alveolar
haemorrhage, requiring mechanical ventilation.
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Ten of the 12 patients involved in the outbreak
presented with pneumonia. The most frequent
clinical symptoms in these ten patients were fever
and respiratory symptoms, although two patients
presented with atypical symptoms and one
was asymptomatic, despite a chest radiograph
demonstrating a new pulmonary inﬁltrate. Two
additional patients were completely asymptom-
atic at the time when urine antigen testing was
performed. Patient no. 3 presented with a large
lung cavitation, persistent fever and persistent
positive sputum cultures, but his condition
steadily improved, with eventual full recovery.
The index patient (no. 1) was diagnosed
initially with atypical pneumonia and was treated
with clarithromycin. Despite early initiation of
macrolide therapy, the patient’s clinical condition
rapidly worsened, with death occurring within
24 h of the diagnosis of pneumonia. Once an
outbreak of LD was suspected and universal
urine antigen testing was performed, all patients
were treated with levoﬂoxacin, including the two
patients with asymptomatic infection. Two more
patients died within 28 days, but their deaths
were considered to be unrelated to the infection.
One patient (no. 2) had a rapid progression of
underlying lung cancer with liver metastases,
with death occurring on the 18th day of levoﬂox-
acin treatment, at which time all signs and
symptoms of pneumonia had disappeared. The
second patient with a positive urine antigen test
without pneumonia (no. 11) was treated with
levoﬂoxacin as an outpatient, but died 21 days
later during a subsequent period of hospitalisa-
Table 1. Baseline characteristics, clinical features and outcome of 12 immunosuppressed patients involved in a nosocomial
outbreak of Legionnaires’ disease in a cancer centre
Patient
no.
Age
(years) Gender
Underlying
disease
Immunosuppressive
therapy
Clinical
symptoms
Radiological
ﬁndings Treatment
Outcome/
time to death
1 41 Male Disseminated,
cancer,
central
nervous
system
metastases
Corticosteroids Dyspnoea,
diarrhoea
Left lower
lobe
inﬁltrate
Clarithromycin
(500 mg
twice daily)
Died ⁄<24 h
2 81 Male Lung
cancer
Corticosteroids Fever,
respiratory
symptoms
Right upper
upper lobe
inﬁltrate
Levoﬂoxacin
(500 mg daily)
Died ⁄ 18 days
3 41 Male Aplastic
anaemia
Corticosteroids,
cytotoxic
chemotherapy,
cyclosporine
Fever,
respiratory
symptoms
Bilateral
inﬁltrates,
cavitation
Levoﬂoxacin
(500 mg
twice daily),
cyclosporine
stopped
Survived
4 61 Male Lung
cancer
Corticosteroids,
radiotherapy
Dyspnoea Right lower
lobe
inﬁltrate
Levoﬂoxacin
(500 mg daily)
ﬂ corticosteroids
Survived
5 43 Female Acute
myeloid
leukaemia,
neutropenia
Cytotoxic
chemotherapy
Fever,
respiratory
symptoms
Multilobar
inﬁltrates
on the
left lung
Levoﬂoxacin
(500 mg
twice daily)
Survived
6 74 Female Lymphoma,
neutropenia
Corticosteroids,
cytotoxic
chemotherapy
Malaise,
diarrhoea
Left lower
lobe
inﬁltrate
Levoﬂoxacin
(500 mg daily),
ﬂ corticosteroids
Survived
7 68 Male Chronic
lymphocytic
leukaemia,
haemolytic
anaemia
Corticosteroids Asymptomatic Left lower
lobe
inﬁltrate
Levoﬂoxacin
(500 mg daily),
ﬂ corticosteroids
Survived
8 57 Female Acute
lymphocytic
leukaemia,
neutropenia,
invasive
pulmonary
aspergillosis
Corticosteroids,
cytotoxic
chemotherapy
Fever,
respiratory
symptoms,
diffuse
alveolar
haemorrhage
Bilateral
inﬁltrates
Levoﬂoxacin
(500 mg
twice daily)
Intensive
care unit
admission,
mechanical
ventilation,
survived
9 68 Female Lymphoma Corticosteroids,
cytotoxic
chemotherapy
Fever Right lower
lobe
inﬁltrate
Levoﬂoxacin
(500 mg daily)
Survived
10 54 Female Lymphoma Corticosteroids Asymptomatic No abnormal
ﬁndings
Levoﬂoxacin
(500 mg daily)
Survived
11 71 Male Pancreatic
cancer
Corticosteroids Asymptomatic No abnormal
ﬁndings
Levoﬂoxacin
(500 mg daily)
Died ⁄ 21 days
12 57 Female Lung
cancer
Corticosteroids,
cytotoxic
chemotherapy
Fever,
respiratory
symptoms
Left lower
lobe
inﬁltrate
Levoﬂoxacin
(500 mg daily)
Survived
1126 Clinical Microbiology and Infection, Volume 13 Number 11, November 2007
 2007 The Authors
Journal Compilation  2007 European Society of Clinical Microbiology and Infectious Diseases, CMI, 13, 1125–1136
tion because of local cancer progression and
massive gastrointestinal bleeding. The attribut-
able case fatality rate was 8.3% (one of 12
patients), and the overall case fatality rate
(£28 days) was 25% (three of 12 patients).
L. pneumophila serogroup 1 was isolated from
ﬁve sputum samples obtained from ﬁve patients
with pneumonia, and also from several samples
obtained from the water system supply. Pulsed-
ﬁeld gel electrophoresis typing indicated that all
the isolates from water systems were identical
and were clonally related to the isolates from
sputum samples. The outbreak, which lasted
4 weeks, was successfully controlled by measures
that included the immediate restriction of water
use, and repeated superheating and ﬂushing of
the water system. After the outbreak, a copper–
silver ionisation unit was installed to provide
permanent reservoir disinfection in conjunction
with ongoing active surveillance of the water
system.
The baseline characteristics of the patients
described here are similar to those found in
earlier studies of LD in immunosuppressed hosts
that reported overall case fatality rates of 50–80%
[10,11]. A previous outbreak occurred during
1985 in a nearby hospital among immunosup-
pressed patients with cancer [10]. At that time,
Legionella urine antigen testing was not available,
and all patients were treated with erythromycin
(plus rifampicin in some cases). The case fatality
rates in the present study were substantially
lower than those in the previous outbreak (attrib-
utable case fatality rates of 8% vs. 43%, and
overall case fatality rates of 25% vs. 50%, respec-
tively).
The present results are in line with recent
reports involving non-immunosuppressed
patients with community-acquired LD, indicating
that early diagnosis, by means of urine antigen
testing and ﬂuoroquinolone therapy, may
improve patient outcome [3–6]. In the outbreak
reported here, universal urine antigen testing
allowed asymptomatic patients to be identiﬁed
at an early stage of Legionella infection. The
prompt treatment of these patients may have
modiﬁed the course of their infection and avoided
the development of pneumonia and a more severe
disease.
Fluoroquinolones have been shown to be more
effective than older macrolides in inhibiting
the intracellular growth of L. pneumophila, both
in vitro and in animal models [12–14]. Improved
outcome (with respect to time to defervescence
and length of hospital stay) for patients treated
with levoﬂoxacin has been documented in three
observational studies [4–6]. The results of the
present study provide additional information
regarding the usefulness of early monotherapy
with levoﬂoxacin for treatment of LD in severely
immunosuppressed patients. However, while
the low patient mortality was probably related
to both universal urine antigen testing and
prompt levoﬂoxacin therapy, the small sample
size and uncontrolled nature of the study mean
that other testing and therapeutic strategies
could have produced similar results. Neverthe-
less, the results suggest that the combined use
of universal urine antigen testing and early
treatment with levoﬂoxacin might improve the
outcome for severely immunosuppressed patients
with LD. This diagnostic and therapeutic
strategy merits consideration when facing a noso-
comial outbreak of LD involving similar patient
populations.
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ABSTRACT
Non-duplicate methicillin-resistant Staphylococcus
aureus (MRSA) isolates (n = 436), collected from
four hospitals located in three Korean cities
between 2001 and 2005, were investigated by
SCCmec typing and multilocus sequence typing
(MLST). Variations within SCCmec, especially
type II, were detected in 165 (37.8%) isolates,
and these variants were characterised using four
different SCCmec typing methods. The predo-
minant SCCmec type was a type II variant that
differed from type II by the absence of a pUB110
insertion. MLST analysis showed that most of the
isolates carrying SCCmec variants belonged to
ST5.
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SCCmec is a mobile element, comprising the mec
gene complex, the ccr gene complex and the
junkyard (J) regions, which can integrate into the
Staphylococcus aureus chromosome [1,2]. In 2001,
Ito et al. [1] described three types of SCCmec
elements (designated I–III), based on the structure
of the mecA complex and the ccrAB allele. Sub-
sequently, SCCmec type IV was identiﬁed, initially
in two community-acquired strains of methicillin-
resistant S. aureus (MRSA) [2,3]. In 2002, Oliveira
and de Lencastre [4] developed a single-step
multiplex PCR (M-PCR) method designed to
provide maximum resolution of the various
structural variants of the SCCmec element, based
on genes located within the J-regions of SCCmec
elements. Although this method did not include
identiﬁcation of the ccrAB allele, it enabled dis-
crimination of the four major SCCmec types and
certain variants, such as IA and IIIA. This method
is simple and easy to perform, and has therefore
been used increasingly, but is limited by its
inability to detect the newly identiﬁed SCCmec
type V and subtypes IVa–IVd [5,6]. Subsequently
Zhang et al. [7] developed a new M-PCR strategy
that has the advantage of identifying the J1 region
of eight SCCmec elements (I, II, III, IVa–IVd and
V) simultaneously.
In the present study, the SCCmec structural
type and sequence type (ST) of 436 clinical isolates
of MRSA were determined. The isolates were
collected from four hospitals located in three
Korean cities between 2001 and 2005. All isolates
were tested for phenotypic resistance to oxacillin
by the salt agar dilution method according to
CLSI (formerly NCCLS) guidelines [8], and for the
presence of the mecA gene by PCR.
To determine the SCCmec structural type, the
M-PCR developed by Oliveira and de Lancastre
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